Trial reportAmerican journal of hematology2016
Transcranial doppler re-screening of subjects who participated in STOP and STOP II.
Trial report in American journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Interventions for preventing silent cerebral infarcts in people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Blood transfusions for treating acute chest syndrome in people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Interventions for preventing silent cerebral infarcts in people with sickle cell disease.The Cochrane database of systematic reviews · 2017Pooled it
- Reduction in transcranial doppler ultrasound (TCD) velocity after regular blood transfusion therapy is associated with a change in hemoglobin S fraction in sickle cell anemia.American journal of hematology · 2020Trial
- Article
- Identified barriers and facilitators to stroke risk screening in children with sickle cell anemia: results from the DISPLACE consortium.Implementation science communications · 2021Article
- Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium.Pediatric blood & cancer · 2020Article
- Testing the Use of Data Drawn from the Electronic Health Record to Compare Quality.Pediatric quality & safetyArticle
- Genetic, laboratory and clinical risk factors in the development of overt ischemic stroke in children with sickle cell disease.Hematology, transfusion and cell therapyReview
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
In children with Sickle Cell Disease, the combination of risk stratification with Transcranial Doppler Ultrasound (TCD) and selective chronic red cell transfusion (CRCT-the STOP Protocol) is one of the most effective stroke prevention strategies in medicine. How fully it is being implemented is unclear. Nineteen of 26 sites that conducted the two pivotal clinical trials (STOP and STOP II) participated in Post STOP, a comprehensive medical records review assessing protocol implementation in the 10-15 years since the trials ended. Professional abstractors identified medical records in the Post STOP era in 2851 (74%) of the 3,840 children who took part in STOP and/or STOP II, and documented TCD rescreening, maintenance of CRCT in those at risk, and stroke. Among 1,896 children eligible for TCD rescreening (target group), evidence of any rescreening was found in 1,090 (57%). There was wide site variation in TCD rescreening ranging from 18% to 91% of eligible children. Both younger age and having a conditional TCD during STOP/II were associated with a higher likelihood of having a TCD in Post STOP. Sixty eight new abnormal, high risk cases were identified. Despite clear evidence of benefit the STOP protocol is not fully implemented even at experienced sites. Site variation suggests that system improvements might remove barriers to implementation and result in even greater reduction of ischemic stroke in children with SCD. Am. J. Hematol. 91:1191-1194, 2016. © 2016 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.